— Trial designed to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of MDNA11 in patients with advanced solid tumors
— Preliminary update on safety, PK/PD, and biomarker data expected by year-end 2021
— Preliminary efficacy readouts from study expected over the course of 2022
